What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Carsten Müller-Tidow focuses on Cancer research, Myeloid leukemia, Leukemia, Myeloid and Molecular biology.
His research in Cancer research intersects with topics in Carcinogenesis, Regulation of gene expression, Receptor tyrosine kinase and Fms-Like Tyrosine Kinase 3.
The study incorporates disciplines such as Genetics, Haematopoiesis, Wnt signaling pathway, DNA methylation and Transcription factor in addition to Myeloid leukemia.
His Leukemia study combines topics from a wide range of disciplines, such as Myelofibrosis, Philadelphia chromosome and Oncology.
His Myeloid study incorporates themes from Cytarabine and Surgery.
His research integrates issues of KDM1A, Chromatin immunoprecipitation, RNA interference, Cyclin-dependent kinase complex and Retinoic acid in his study of Molecular biology.
His most cited work include:
- MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. (1471 citations)
- Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia (484 citations)
- The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. (391 citations)
What are the main themes of his work throughout his whole career to date?
Carsten Müller-Tidow mainly investigates Cancer research, Internal medicine, Myeloid leukemia, Leukemia and Oncology.
His Cancer research research includes themes of Haematopoiesis, Stem cell, DNA methylation, Immunology and Receptor tyrosine kinase.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery.
Carsten Müller-Tidow interconnects Fms-Like Tyrosine Kinase 3, Myeloid, Acute promyelocytic leukemia, Transcription factor and Molecular biology in the investigation of issues within Myeloid leukemia.
The concepts of his Molecular biology study are interwoven with issues in Gene expression and Gene.
His work on Chemotherapy regimen as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science.
He most often published in these fields:
- Cancer research (47.74%)
- Internal medicine (34.21%)
- Myeloid leukemia (34.40%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (34.21%)
- Cancer research (47.74%)
- Oncology (20.68%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Cancer research, Oncology, Myeloid leukemia and Transplantation.
As a part of the same scientific study, he usually deals with the Internal medicine, concentrating on Gastroenterology and frequently concerns with Concomitant, Immunosuppression and AL amyloidosis.
His Cancer research research includes elements of Haematopoiesis, T cell, Antigen, Single-cell analysis and Bone marrow.
His work carried out in the field of Oncology brings together such families of science as B-cell lymphoma, Adverse effect and Mantle cell lymphoma.
His studies deal with areas such as Myeloid, Newly diagnosed, Gene, Leukemia and Fludarabine as well as Myeloid leukemia.
His Transplantation research incorporates themes from Cytarabine, Chemotherapy, Clinical endpoint and Cumulative incidence.
Between 2019 and 2021, his most popular works were:
- Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria (25 citations)
- Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia (12 citations)
- A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. (11 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His main research concerns Internal medicine, Myeloid leukemia, Cancer research, Oncology and Multiple myeloma.
His Internal medicine research focuses on Gastroenterology and how it connects with Concomitant, AL amyloidosis and Transplantation.
His Myeloid leukemia research integrates issues from Prognostic variable, Small nucleolar RNA, Cell growth, Myeloid and Leukemia.
Carsten Müller-Tidow has included themes like Progenitor cell, Haematopoiesis and Stem cell in his Myeloid study.
His studies in Cancer research integrate themes in fields like Ex vivo, Amanitin, Tumour heterogeneity, Gene expression profiling and Single-cell analysis.
The Oncology study combines topics in areas such as Newly diagnosed and Adverse effect.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
